成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Clinical Cardiology >>article
Clinical Cardiology

Clinical Cardiology

IF: 2.39
Download PDF

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis

Published:20 May 2021 DOI: 10.1002/clc.23643 PMID: 34013998
Linggen Gao MD, Bin Wang MD, Ying Pan MD, Yan Lu MD, Rui Cheng MD

Abstract

The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. Febuxostat had a better safety outcome compared with allopurinol. In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles published between March 1, 2000 and April 4, 2021, without any language restrictions. We did a systematic review and meta-analysis of included clinical trials to evaluate the cardiovascular safety of febuxostat compared to allopurinol for treatment of chronic gout. Two reviewers independently selected studies, assessed study quality, and extracted data. Risk ratios were calculated with random effects and were reported with corresponding 95% confidence intervals (CI). From 240 potentially relevant citations, 224 papers were excluded; 16 studies were ultimately included in the analysis. Febuxostat had a better safety outcome compared with allopurinol,which was the composite of urgent coronary revascularization (OR: 0.84, 95% CI: 0.77–0.90, p?<?.0001) and stroke (OR: 0.87, 95% CI: 0.79–0.97, p?=?.009). However, that difference was not found in nonfatal myocardial infarction (OR: 0.99, 95% CI: 0.80–1.22, p?=?.91), cardiovascular related mortality (OR: 0.98, 95% CI: 0.69–1.38, p?=?.89) and all-cause mortality (OR: 0.93, 95% CI: 0.75–1.15, p?=?.52). No significant differences in cardiovascular related mortality and all-cause mortality were observed across any subgroup. This meta-analysis adds new evidence regarding the cardiovascular safety of febuxostat in patients. Initiation of febuxostat in patients was not associated with an increased risk of death or serious cardiovascular related adverse events compared with allopurinol.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Febuxostat 144060-53-7 C16H16N2O3S 872 suppliers $5.00-$5690.00
Allopurinol 315-30-0 C5H4N4O 857 suppliers $5.00-$2285.00

Similar articles

IF:3.4

Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis

Advances in Therapy Sofia Tejada, Raquel Martinez-Reviejo,etc Published: 25 July 2022
IF:2

Exposure to Nitrofurantoin During Early Pregnancy and Congenital Malformations: A Systematic Review and Meta-Analysis

Journal of obstetrics and gynaecology Canada Ori Goldberg MD, MPH ,etc Published: 1 February 2015